Based on the Chiome Bioscience Inc stock forecast from 0 analysts, the average analyst target price for Chiome Bioscience Inc is not available over the next 12 months. Chiome Bioscience Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Chiome Bioscience Inc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Chiome Bioscience Inc’s stock price was JPY 235.00. Chiome Bioscience Inc’s stock price has changed by +0.43% over the past week, +56.67% over the past month and +76.69% over the last year.
No recent analyst target price found for Chiome Bioscience Inc
No recent average analyst rating found for Chiome Bioscience Inc
Company Overview Chiome Bioscience Inc
Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide. The company operates through two segments, Drug Discovery Business and Drug Discovery Support Business. It offers ADLib System, a monoclonal antibody generating system for drug discovery and development; and Human ADLib System, a chicken antibody gene converted to humanized antibodies. The company also provides protein expression and purification services; stable cell line generation services for recombinant protein and antibody production; and antibody generation services using the ADLib system or B cell cloning techniques. Its product pipeline comprises ADCT-701, an anti-dlk1 antibody for treating liver cancer which is under phase 1 trial; CBA-1205, an afucosylated anti-dlk1 antibody for liver cancer, lung cancer, and neuroblastoma which is under phase 1 trial; and CBA-1535, an anti 5T4/WAIF1 antibody for malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, and breast cancer (TNBC) which is under phase 1 trial. The company's product pipeline under preclinical study includes LIV-2008/2008b, an anti-TROP-2 antibody for the treatment of TNBC, lung cancer, and colorectal cancer; BMAA, an anti-semphorin3a antibody for treating central, immune/ inflammatory diseases, neurological disorder, and ophthalmic diseases; PCDC, an anti- CDCP1 antibody for lung, colorectal, pancreatic, breast, and ovarian tumors; PTRY, an antibody 5T4/CD3/PD-L1 for treating malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, triple negative breast cancer; and PFKR, anti-CX3CR1 antibody for secondary progressive multiple sclerosis. It serves universities, research institutions, and pharmaceutical companies. Chiome Bioscience Inc. was incorporated in 2005 and is headquartered in Tokyo, Japan. Read Less
Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide. The company operates through two segments, Drug Discovery Business and Drug Discovery Support Business. It offers ADLib System, a monoclonal antibody generating system...Read More
Frequently Asked Questions About Chiome Bioscience Inc (4583:TSE) Stock
Stock Target Advisor's fundamental analysis for Chiome Bioscience Inc's stock is Bearish.
Unfortunately we do not have enough data on 4583:TSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 4583:TSE's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 4583:TSE's stock to indicate if its overvalued.
The last closing price of 4583:TSE's stock was JPY 235.00.
The most recent market capitalization for 4583:TSE is JPY 6.12B.
Unfortunately we do not have enough analyst data on 4583:TSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Chiome Bioscience Inc's stock.
As per our most recent records Chiome Bioscience Inc has 0 Employees.
Chiome Bioscience Inc's registered address is Sumitomo Fudosan Nishi-shinjuku Bldg.No.6, Tokyo, Japan, 151-0071.
You can get more information about it from Chiome Bioscience Inc's website at https://www.chiome.co.jp.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Chiome Bioscience Inc (4583:TSE) Stock
Stock Target Advisor's fundamental analysis for Chiome Bioscience Inc's stock is Bearish.
Unfortunately we do not have enough data on 4583:TSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 4583:TSE's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 4583:TSE's stock to indicate if its overvalued.
The last closing price of 4583:TSE's stock was JPY 235.00.
The most recent market capitalization for 4583:TSE is JPY 6.12B.
Unfortunately we do not have enough analyst data on 4583:TSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Chiome Bioscience Inc's stock.
As per our most recent records Chiome Bioscience Inc has 0 Employees.
Chiome Bioscience Inc's registered address is Sumitomo Fudosan Nishi-shinjuku Bldg.No.6, Tokyo, Japan, 151-0071.
You can get more information about it from Chiome Bioscience Inc's website at https://www.chiome.co.jp.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 4583:TSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
